News
Clinical trials now under way or recently completed have the potential to make new therapeutic options available soo…
Michael Ammar, MD; and Jason Hsu, MD
It is tempting to observe the retina therapeutics and pharmacology pipeline the way we watch a horse race -- which c…
Pravin U. Dugel, MD
The names of new drugs, studies, and companies fly around at retina meetings. It can be difficult to keep the names …
Priyatham (Prithu) S. Mettu, MD
The inaugural Future is Now: Leaders in Ocular Gene Therapy Meeting, focusing on gene therapy in ophthalmology, took…
Kourous A. Rezaei, MD
Retina Today: The uveitis pipeline is busy. From a high level, what should retina specialists be aware of?
Steven…
With Steven Yeh, MD
Telemedicine is on the rise. Today, the landscape of telemedicine ranges from remote patient consultations to handhe…
John B. Miller, MD; and Rebecca Zeng, BA; With Sidebar Commentary by Judy E. Kim, MD
There is no doubt that anti-VEGF therapy has revolutionized care for individuals w
Jeffrey S. Heier, MD; Allen C. Ho, MD; and Robert L. Avery, MD
Gene therapy has long been imagined as a potential treatment approach for wet age-related macular degeneration (AMD)…
Szilárd Kiss, MD
